Shire’s (SHP) “Overweight” Rating Reiterated at Morgan Stanley
Shire (LON:SHP)‘s stock had its “overweight” rating restated by equities researchers at Morgan Stanley in a report issued on Thursday. They presently have a GBX 5,700 ($78.75) price objective on the biopharmaceutical company’s stock. Morgan Stanley’s price objective indicates a potential upside of 81.38% from the stock’s previous close.
SHP has been the topic of a number of other reports. Shore Capital reissued a “buy” rating on shares of Shire in a research report on Monday, November 13th. Liberum Capital dropped their price target on Shire from GBX 4,400 ($60.79) to GBX 4,200 ($58.03) and set a “hold” rating on the stock in a research report on Tuesday, October 24th. HSBC dropped their price target on Shire from GBX 4,050 ($55.95) to GBX 3,800 ($52.50) and set a “hold” rating on the stock in a research report on Tuesday, November 21st. Deutsche Bank reissued a “buy” rating on shares of Shire in a research report on Monday, December 11th. Finally, Citigroup restated a “buy” rating and issued a GBX 5,500 ($75.99) price objective on shares of Shire in a report on Friday, January 5th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Shire currently has an average rating of “Buy” and an average target price of GBX 5,163.89 ($71.34).
Shares of Shire (SHP) opened at GBX 3,142.50 ($43.42) on Thursday. Shire has a 12-month low of GBX 3,034 ($41.92) and a 12-month high of GBX 5,067 ($70.01). The company has a market capitalization of $28,790.00 and a P/E ratio of 603.17.
ILLEGAL ACTIVITY WARNING: “Shire’s (SHP) “Overweight” Rating Reiterated at Morgan Stanley” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/15/shires-shp-overweight-rating-reiterated-at-morgan-stanley.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.